dinkuminvestor, you are wrong. Anyone who buys just because of news and management's response to the news is a fair weather investor. Only people who do the research and understand the company are worthwhile having around. I am not supporting management, or otherwise. I just think we should direct our criticisms to the real issues, which includes remuneration, legal settlements, failure to have more advanced drug candidates.
